CANCER BIOLOGICS MARKET ANALYSIS(2020-2027) - PowerPoint PPT Presentation

View by Category
About This Presentation



Read here the market research report on the “Cancer Biologics Market” published by CMI team – PowerPoint PPT presentation

Number of Views:2
Date added: 4 November 2020
Slides: 18
Provided by: kunalbhuta
Category: Other


Write a Comment
User Comments (0)
Transcript and Presenter's Notes


  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//
  • COVID-19 Impact Tracker

  • Cancer Biologics Market, by Product (Monoclonal
    Antibodies, Cytokine-Based Immunotherapy, Cancer
    Vaccines, CAR-T Cell Therapy, and Immune
    Checkpoint Inhibitors), by Application (Non-small
    Cell Lung Cancer, Prostate Cancer, Breast Cancer,
    Acute Myeloid Leukemia, Lymphoma, Multiple
    Myeloma, Ovarian Cancer, Colorectal Cancer,
    Gastric Cancers, and Others), by Distribution
    Channel (Hospitals, Clinics, and Others), and by
    Region (North America, Latin America, Europe,
    Middle East, Asia Pacific, and Africa) - Size,
    Share, Outlook, and Opportunity Analysis, 2020 -

  • Biologic drug is a product that contain
    components of living organisms such as animal,
    human, or produced from living organisms.
    Antibodies, vaccines, and interleukins are some
    examples of biologic drugs. Furthermore, biologic
    drugs are administrated by injection or infusion,
    as biologic products can easily lose their
    potency due to acid present in the stomach, if
    administered by oral route to the patient.
    Moreover, biologic drug for cancer treatment
    helps to increase the bodys ability to fight
    against various types of cancers such as
    nasopharyngeal cancer, prostate cancer, breast
    cancer, neck cancer, and lung cancer.
    Pembrolizumab, Atezolizumab, Cemiplimab-rwlc,
    Blinatumomab and Durvalumab are few examples of
    biologic drugs that are used for the treatment of

Global Cancer Biologics Market Drivers
  • The global cancer biologics market is expected to
    witness significant growth over the forecast
    period, owing to increasing approvals of biologic
    drug by regulatory authorities for the treatment
    of cancer. For instance, in 2018, the U.S Food
    and Drug Administration (FDA) approved
    blinatumomab, for the patient suffering from
    B-cell precursor acute lymphoblastic leukemia,
    which show reduction in the severity of the
    disease, as the minimal residual disease (MRD) is
    found to be greater than or equal to 0.1.
    Furthermore, in 2018, U.S FDA approved
    Cemiplimab-rwlc, for the treatment metastatic
    advanced stage cutaneous squamous cell cancer.
    The recommended Cemiplimab-rwlc dose for the
    patient is 350 mg, which is administrated as
    intravenous infusion over 30 minutes, in every
    three weeks.

  • Moreover, in January 2020, F. Hoffmann-La Roche
    AG announced about its submission of supplemental
    biological license to U.S Food and Drug
    Administration (FDA) for Tecentriq
    (atezolizumab), in combination with Avastin
    (bevacizumab) drug for most common form of liver
    cancer. Therefore, increasing number of
    regulatory approvals of biologic drug for the
    treatment of cancer, is expected to boost of
    cancer biologics market growth over the forecast

  • Global Cancer Biologics Market Restraints
  • However, high cost associated with cancer
    biologic drug is one of the major restraint that
    is expected to hamper the global cancer biologics
    market growth. For instance, cost of blinatumomab
    is US 17,800 per year. Furthermore, side effects
    associated with cancer biologic drug such as
    allergic reactions, injection site reactions,
    weakness, diarrhea, nausea, vomiting, and rash
    yet remains another factor hindering the global
    cancer biologics market growth.

  • Global Cancer Biologics Market Regional Analysis
  • North America is expected to account for highest
    market share in the global cancer biologics
    market, owing to increasing prevalence of cancer,
    among people in North America. For instance, in
    2019, in the U.S, according to the American
    Cancer Societys (ACS), around 1,762,450 new
    cancer cases were diagnosed, and 606,880 new
    cancer deaths were reported.
  • Furthermore, increasing drug approvals for the
    treatment of metastatic merkel cell carcinoma
    (MCC) by the company is one of the factors that
    is driving the global cancer biologic market
    growth. For instance, in 2018, pembrolizumab recei
    ved approval from the U.S. Food and Drug
    Administration (FDA) for the treatment of
    patients suffering from metastatic Merkel cell
    carcinoma (MCC).

  • Europe is expected to account for second highest
    market share in the global cancer biologics
    market, owing to increasing prevalence of cancer
    in Europe region. For instance, in 2018, around
    3.9 million of cancer with new cases excluding
    non-melanoma skin cancer, and 1.9 million death
    from cancer were reported by the International
    Agency for Research on Cancer (IARC), in
    collaboration with the European Network of Cancer
    Registries (ENCR, as well as the European
    Commissions Joint Research Centre (JRC).

  • Moreover, Asia Pacific is expected to exhibit
    CAGR over the forecast period due to the
    increasing approval of drugs by regulatory bodies
    for the treatment of Hodgkin's disease (blood
    cancer) by the company. For instance, in 2018,
    National Medical Products Administration (NMPA)
    of China approved Sintilimab injection, which is
    sold under the brand name Tyvyt, and was jointly
    announced by Innovent Biologics, Inc. and Eli
    Lilly and Company. Sintilimab injection is used
    for the treatment of Hodgkin's disease (blood
    cancer), and is fully human IgG4 monoclonal

  • Global Cancer Biologics Market Key Players
  • Key players operating in the global cancer
    biologic market are Merck Co., Inc., Novartis
    International AG, F. Hoffmann-La Roche AG, Eli
    Lilly and Company, Bristol-Myers Squibb Company,
    Amgen Inc., Pfizer Inc., Sanofi S.A., Bayer AG,
    EnGeneIC Ltd, and GlaxoSmithKline PLC.

  • Market Taxonomy
  • On the basis of product, the global cancer
    biologics market is segmented into
  • Monoclonal Antibodies
  • Naked Monoclonal Antibodies
  • Conjugated Monoclonal Antibodies
  • Chemo labeled Antibodies
  • Radiolabeled Antibodies
  • Bispecific Monoclonal Antibodies
  • Cytokine-Based Immunotherapy
  • Cancer Vaccines
  • Treatment Vaccines
  • Preventive Vaccines
  • CAR-T Cell Therapy
  • Immune Checkpoint Inhibitors
  • CTL-4 Checkpoint Inhibitor
  • PD-1 PD-L1 Checkpoint Inhibitor

  • On the basis of application, the global cancer
    biologics market is segmented into
  • Non-Small Cell Lung Cancer
  • Prostate Cancer 
  • Breast Cancer
  • Acute Myeloid Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Ovarian Cancer
  • Colorectal Cancer
  • Gastric Cancers
  • Others

  • On the basis of distribution channel, the global
    cancer biologics market is segmented into
  • Hospital
  • Clinic
  • Others
  • On the basis of region, the global cancer
    biologics market is segmented into
  • North America
  • Latin America
  • Europe
  • Middle East
  • Asia Pacific
  • Africa

  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Buy Now
  • Referencehttps//

About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
  • Phone 1-206-701-6702
  • Email

  • Thank You!
  • Kindly follow CMI Social Media
    Profiles for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//